Julius-von-Sachs Institute for Biological Sciences, University of Würzburg, Würzburg, Germany.
Mar Drugs. 2010 Feb 23;8(2):373-80. doi: 10.3390/md8020373.
Actinomycetes are prolific producers of pharmacologically important compounds accounting for about 70% of the naturally derived antibiotics that are currently in clinical use. In this study, we report on the isolation of Streptomyces sp. strains from Mediterranean sponges, on their secondary metabolite production and on their screening for anti-infective activities. Bioassay-guided isolation and purification yielded three previously known compounds namely, cyclic depsipeptide valinomycin, indolocarbazole alkaloid staurosporine and butenolide. This is the first report of the isolation of valinomycin from a marine source. These compounds exhibited novel anti-parasitic activities specifically against Leishmania major (valinomycin IC(50) < 0.11 microM; staurosporine IC(50) 5.30 microM) and Trypanosoma brucei brucei (valinomycin IC(50) 0.0032 microM; staurosporine IC(50) 0.022 microM; butenolide IC(50) 31.77 microM). These results underscore the potential of marine actinomycetes to produce bioactive compounds as well as the re-evaluation of previously known compounds for novel anti-infective activities.
放线菌是具有丰富的产生药理学上重要化合物的能力的微生物,占目前在临床上使用的天然来源抗生素的约 70%。在这项研究中,我们报告了从地中海海绵中分离的链霉菌属菌株,它们的次生代谢产物的产生情况,以及它们对抗感染活性的筛选情况。基于生物测定的分离和纯化得到了三种先前已知的化合物,即环二肽缬氨霉素、吲哚咔唑生物碱司替罗星和丁烯内酯。这是首次从海洋来源中分离出缬氨霉素。这些化合物表现出针对利什曼原虫(缬氨霉素 IC(50)<0.11μM;司替罗星 IC(50)5.30μM)和布氏锥虫(缬氨霉素 IC(50)0.0032μM;司替罗星 IC(50)0.022μM;丁烯内酯 IC(50)31.77μM)的新型抗寄生虫活性。这些结果强调了海洋放线菌产生生物活性化合物的潜力,以及重新评估先前已知化合物的新型抗感染活性的重要性。